Please login to the form below

Not currently logged in
Email:
Password:

trastuzumab

This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

CHMP meeting round-up. Among other highlights the CHMP backed two biosimilar medicines - Amgen’s Kanjinti version of Roche’s Herceptin (trastuzumab) for the treatment of breast and gastric cancer and

Latest news

  • Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

    Mundipharma has strengthened its partnership with biopharmaceutical group Celltrion Healthcare by securing rights to its trastuzumab biosimilar. ... As per terms of the deal, Mundipharma - a global network of privately owned independent companies - has

  • MSD launches EU’s first biosimilar Herceptin in UK MSD launches EU’s first biosimilar Herceptin in UK

    Herceptin (trastuzumab) was Roche’s second-biggest product last year, bringing in more than CHF 7bn ($7.4bn), and the onset of biosimilar competition in Europe is expected to start to ... The biggest category of medicines in oncology is monoclonal

  • Novartis doubles down on biosimilars with Biocon alliance Novartis doubles down on biosimilars with Biocon alliance

    drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA. ... Biocon meanwhile has launched an insulin glargine biosimilar in Japan to rival Sanofi’s Lantus brand,

  • Mylan gets first biosimilar Herceptin OK from FDA Mylan gets first biosimilar Herceptin OK from FDA

    The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin

  • First Herceptin biosimilar cleared in Europe First Herceptin biosimilar cleared in Europe

    The South Korea-based joint venture between Samsung and Biogen says the new biosimilar, called Ontruzant, has been approved for the full range of registered indications for Herceptin (trastuzumab), including early ... We hope Ontruzant will play an

More from news
Approximately 15 fully matching, plus 147 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics